Vascular Solutions (NASDAQ: VASC) and Myriad Genetics (NASDAQ:MYGN) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations and institutional ownership.

Profitability

This table compares Vascular Solutions and Myriad Genetics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Vascular Solutions 13.02% 15.78% 14.30%
Myriad Genetics 2.83% 9.67% 5.75%

Insider and Institutional Ownership

80.2% of Vascular Solutions shares are owned by institutional investors. 6.9% of Vascular Solutions shares are owned by insiders. Comparatively, 6.2% of Myriad Genetics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Vascular Solutions and Myriad Genetics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Vascular Solutions N/A N/A N/A $0.70 80.00
Myriad Genetics $771.40 million 2.68 $97.70 million $0.32 94.53

Myriad Genetics has higher revenue and earnings than Vascular Solutions. Vascular Solutions is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Vascular Solutions and Myriad Genetics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vascular Solutions 0 4 0 0 2.00
Myriad Genetics 2 6 1 0 1.89

Vascular Solutions currently has a consensus price target of $55.50, suggesting a potential downside of 0.89%. Myriad Genetics has a consensus price target of $20.38, suggesting a potential downside of 32.64%. Given Vascular Solutions’ stronger consensus rating and higher probable upside, equities analysts plainly believe Vascular Solutions is more favorable than Myriad Genetics.

Volatility and Risk

Vascular Solutions has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500. Comparatively, Myriad Genetics has a beta of 0.25, suggesting that its share price is 75% less volatile than the S&P 500.

Summary

Vascular Solutions beats Myriad Genetics on 9 of the 11 factors compared between the two stocks.

Vascular Solutions Company Profile

Vascular Solutions, Inc. is a medical device company focused on bringing clinically advanced solutions to the market for treating coronary and peripheral vascular disease. The Company’s product line consists of devices and services that are sold to interventional cardiologists, interventional radiologists, electrophysiologists and vein practices around the world. Its products include GuideLiner catheters, Pronto catheters, Vein catheter reprocessing, Micro-introducer kits, Hemostatic patches, Radial access products, Langston catheters and D-Stat Flowable hemostat. The Company’s product portfolio includes a spectrum of over 90 products consisting of approximately 900 stock keeping units (SKUs) covering an array of blood clotting devices, extraction catheters, access catheters, guide extension catheters, micro-introducer kits, guidewires, snare and retrieval devices, a reprocessing service for radiofrequency catheters and a laser and procedure kits for the treatment of varicose veins.

Myriad Genetics Company Profile

Myriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology. Its molecular diagnostic tests include myRisk Hereditary Cancer, BRACAnalysis CDx and COLARIS.

Receive News & Ratings for Vascular Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Solutions Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.